Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $143.2 billion, the company offers ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer (PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings of $0.64 per share, down 39.6% year-over-year, on revenue of $16.52 billion, ...

A month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Pfizer issued its 2026 guidance, expecting its adjusted earnings per share to come in below this year's figures, and revised its 2025 revenue outlook. The company reiterated its 2025 adjusted earnings ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...

Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...

Both Ford and Pfizer have very attractive dividend yields.